众生药业：公司的RAY1225注射液已获得FDA批准在美国开展超重或肥胖患者的II期临床研究

Core Viewpoint - The company, Zhongsheng Pharmaceutical, has received FDA approval to conduct Phase II clinical trials for its RAY1225 injection in overweight or obese patients in the United States, indicating a significant step in its international market expansion strategy [1] Group 1 - The company emphasizes the importance of overseas market opportunities for its products [1] - The company is accelerating its internationalization efforts [1]